請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19200
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | Yu-Lin Tseng | en |
dc.contributor.author | 曾鈺霖 | zh_TW |
dc.date.accessioned | 2021-06-08T01:48:34Z | - |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-02 | |
dc.identifier.citation | 1. 衛生福利部, 103年死因統計結果分析. 2014.
2. Bruix, J., M. Sherman, and D. American Association for the Study of Liver, Management of hepatocellular carcinoma: an update. Hepatology, 2011. 53(3): p. 1020-2. 3. El-Serag, H.B., Hepatocellular carcinoma. N Engl J Med, 2011. 365(12): p. 1118-27. 4. Venook, A.P., et al., The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 2010. 15 Suppl 4: p. 5-13. 5. Terrault, N.A., et al., AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016. 63(1): p. 261-83. 6. Han, S.H. and T.T. Tran, Management of Chronic Hepatitis B: An Overview of Practice Guidelines for Primary Care Providers. J Am Board Fam Med, 2015. 28(6): p. 822-37. 7. Schuppan, D. and N.H. Afdhal, Liver cirrhosis. Lancet, 2008. 371(9615): p. 838-51. 8. Fattovich, G., et al., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 2004. 127(5 Suppl 1): p. S35-50. 9. El-Serag, H.B. and K.L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007. 132(7): p. 2557-76. 10. Sanyal, A.J., S.K. Yoon, and R. Lencioni, The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist, 2010. 15 Suppl 4: p. 14-22. 11. Wiemann, S.U., et al., Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. Faseb j, 2002. 16(9): p. 935-42. 12. Hoshida, Y., et al., Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology, 2013. 144(5): p. 1024-30. 13. Kim, M.N., et al., Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology, 2015. 61(6): p. 1851-9. 14. Liaw, Y.F., et al., Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004. 351(15): p. 1521-31. 15. WHO Guidelines Approved by the Guidelines Review Committee, in Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015, World Health Organization Copyright (c) World Health Organization 2015.: Geneva. 16. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012. 57(1): p. 167-85. 17. 衛生福利部中央健康保險署, 全民健康保險藥品給付規定-105年版. 2016. 18. Singal, A.G., et al., Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev, 2012. 21(5): p. 793-9. 19. Singal, A., et al., Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 2009. 30(1): p. 37-47. 20. Zhang, B.H., B.H. Yang, and Z.Y. Tang, Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol, 2004. 130(7): p. 417-22. 21. Wu, C.Y., et al., Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut, 2016. 65(4): p. 693-701. 22. Hung, Y.C., et al., Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology, 2015. 61(6): p. 1934-44. 23. Yang, H.I., et al., Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol, 2011. 12(6): p. 568-74. 24. Wong, V.W., et al., Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol, 2010. 28(10): p. 1660-5. 25. Yuen, M.F., et al., Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol, 2009. 50(1): p. 80-8. 26. Abu-Amara, M., et al., The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut, 2015. 27. Pugh, R.N., et al., Transection of the oesophagus for bleeding oesophageal varices. Br J Surg, 1973. 60(8): p. 646-9. 28. Flemming, J.A., et al., Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer, 2014. 120(22): p. 3485-93. 29. Kamath, P.S. and W.R. Kim, The model for end-stage liver disease (MELD). Hepatology, 2007. 45(3): p. 797-805. 30. Iasonos, A., et al., How to build and interpret a nomogram for cancer prognosis. J Clin Oncol, 2008. 26(8): p. 1364-70. 31. Bilchick, K.C., et al., Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol, 2012. 60(17): p. 1647-55. 32. Roulot, D., et al., Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol, 2008. 48(4): p. 606-13. 33. Wong, G.L., et al., Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol, 2008. 6(9): p. 1027-35. 34. Smith, R.A., et al., Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin, 2015. 65(1): p. 30-54. 35. Esserman, L.J., et al., A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn, 2007. 7(5): p. 533-44. 36. Brothers, J.F., et al., Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med, 2013. 11: p. 168. 37. Aniwan, S., et al., A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants. Gastrointest Endosc, 2015. 81(3): p. 719-27. 38. de-Torres, J.P., et al., Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med, 2015. 191(3): p. 285-91. 39. Saffroy, R., et al., New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med, 2007. 45(9): p. 1169-79. 40. Calvaruso, V. and A. Craxi, Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int, 2014. 34 Suppl 1: p. 85-90. 41. Hadziyannis, S.J., et al., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006. 131(6): p. 1743-51. 42. Marengo, A., et al., Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort. Antivir Ther, 2013. 18(1): p. 87-94. 43. Marcellin, P., et al., Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med, 2008. 359(23): p. 2442-55. 44. Chen, C.J., et al., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama, 2006. 295(1): p. 65-73. 45. Sinn, D.H., et al., Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology, 2015. 62(3): p. 694-701. 46. Yu, M.W., et al., Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst, 2000. 92(14): p. 1159-64. 47. Koh, W.P., et al., Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer, 2011. 105(9): p. 1430-5. 48. Lee, M.H., et al., Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology, 2013. 58(2): p. 546-54. 49. El-Serag, H.B., et al., A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology, 2014. 146(5): p. 1249-55.e1. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19200 | - |
dc.description.abstract | 背景:
許多B型肝炎帶原者是具有臨床前期肝硬化,而這類臨床前期肝硬化者是肝細胞癌的風險族群。現今超音波影像被廣泛應用在偵測肝硬化與肝細胞癌上,在臨床上每次以超音波檢測肝硬化的結果,可能會隨著時間而有所變動,對於此現象是否會影響後續發生肝細胞癌的風險目前仍是未知的。本篇研究利用幾個長期追蹤的B型肝炎帶原者研究世代,分別有以下幾點目的: 1) 評估在不同特性的研究世代中,以超音波檢測出的肝硬化者,其短期、長期的肝細胞癌累積發生率。 2) 評估先前從B型肝炎帶原者中,所發展出的肝細胞癌危險分數,是否可以有效應用在以超音波檢測的肝硬化者上。 3) 針對以超音波檢測的肝硬化者,發展出肝細胞癌風險預測模式,並且評估此模式的預測能力。 材料與方法: 所有的資料是來自於三個長期追蹤的B型肝炎追蹤世代,年齡為20-80歲、無肝細胞癌病史,並且至少有一次(或以上)的超音波檢測,最後總共有5577位B型肝炎帶原者進入研究當中,研究個案資料的收集,包含基本人口學、生活史、超音波檢測、肝功能指標。在追蹤期間總共有24627次超音波檢查,其中有467位個案是以超音波檢測出一次(或以上)肝硬化。使用Kaplan-Meier來估計肝細胞癌的累積發生率,以及利用Cox proportional hazards regression來找出肝細胞癌的危險因子。在三個研究世代當中,選擇其中一個作為training set用以建構預測模型,另外兩個則作為validation set,用以驗證並且評估預測模式。利用Area under receiver operating characteristic (AUROC)、integrated discrimination improvement (IDI)、net reclassification improvement (NRI)來評估預測模型的表現,此外透過Nomogram的方法來建構危險分數,用以估計肝硬化者後續發生肝細胞癌的風險。 結果: B型肝炎帶原者在平均追蹤12.75年後,總共有246位研究個案發生肝細胞癌。而利用超音波偵測之肝硬化者,10年之肝細胞癌之累積發生率在三個研究世代中為15至23%,其差異主要來自於各追蹤世代中,性別與年齡的分布不同。在肝硬化者中,以先前研究發展出的肝細胞癌危險分數、追蹤時是否有再次檢測出肝硬化、追蹤時丙胺酸轉氨酶(Alanine Aminotransferase; ALT)異常與否皆能有效預測肝細胞癌的發生,並且有達到統計顯著。單獨以先前研究發展出的肝細胞癌危險分數,預測肝硬化者5年、10年的肝細胞癌之AUC為0.71 (95% confidence interval [CI]: 0.60-0.82)與0.66 (95% CI: 0.57-0.74),而在加入追蹤時是否有再次檢測出肝硬化與ALT異常與否後,預測肝硬化者5年、10年的肝細胞癌之AUC上升至0.81 (0.74-0.89)與0.73 (0.66-0.81),此外,模式預測5年、10年肝細胞癌之IDI為0.125 (p=0.0019)與0.078 (p=0.0002),而NRI則為0.500 (p=0.0010)與0.351 (p=0.0020)。在validation set當中,以nomogram轉換之危險分數的預測效果良好,預測5年、10年肝細胞癌之AUC分別為0.75 (95% CI: 0.67-0.83)與0.77 (95% CI: 0.71-0.84)。 結論: 本研究針對臨床前期肝硬化者所發展出來的危險分數,在不同特性族群上都有的表現,並且應該能應用至其他B型肝炎的族群中。使用此危險分數可以區分出具有不同肝細胞癌風險的B型肝炎肝硬化者,並能藉此來協助臨床上的篩檢與治療策略。 | zh_TW |
dc.description.abstract | Background:
Many hepatitis B virus (HBV) carriers with cirrhosis are subclinical. Subclinical liver cirrhosis as measured by abdominal ultrasonography is strongly associated with an increased risk for hepatocellular carcinoma (HCC). Ultrasonography is now widely used in the diagnosis of liver cirrhosis for HCC screening. Whether a change over time in clinically measured ultrasonographic features influences HCC risk is unknown. With the use of a pooled longitudinal cohort database of HBV carriers, the purposes of this study are: 1) to establish the short-term and long-term cumulative risk for HCC in cirrhosis detected by ultrasonography across cohorts; 2) to investigate whether a HCC screening risk score previously associated with HCC in HBV carriers is prognostic for patients with cirrhosis detected by ultrasonogrpahy; and 3) to develop a novel prediction model for HCC in patients with cirrhosis detected by ultrasonography and evaluate its performance. Materials & Methods: From 1988 to 2010, data on demographics, lifestyle, ultrasonography, and liver biochemistry were collected prospectively on 5577 HBV carriers aged 20-80 years from three cohorts, who were free of HCC and underwent at least one ultrasonography measurement. There were 24627 ultrasonography measurements from participants; of whom 467 were diagnosed with cirrhosis. The Kaplan-Meier method was used to estimate cumulative risk. Cox proportional hazards regression was used to identify predictors for HCC. A subcohort was used as the training set to guide the building of the risk model, and other two subcohorts were used to test the validity and transportability of the risk model. Area under receiver operating characteristic curve (AUROC), integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were used to evaluate prediction model performance. A nomogram construction strategy that combined the HCC screening risk score with routine clinical tests were used to evaluate individual risk. Results: During a mean follow-up of 12.75 years, we identified 246 HCC cases. The 10-years cumulative HCC incidence was estimated to be 15%-23% in three cohorts, depending on distributions of age and sex. HCC screening risk score, the presence or absence of liver cirrhosis in repeated measurement, and follow-up alanine aminotransferase (ALT) activity were statistically significant independent predictors of HCC risk. AUROCs analyses revealed that using the HCC screening risk score alone predicted HCC with an accuracy of 0.71 (95% confidence interval [CI]: 0.60-0.82) and 0.66 (95% CI: 0.57-0.74) in 5- and 10-years, respectively. The addition of liver cirrhosis and ALT during follow-up into the nomogram improved the predictive performance, showing the corresponding AUCs of 0.81 (95% CI: 0.74-0.89, it is significant in comparison with the model including the HCC screening risk score) and 0.73 (95% CI: 0.66-0.81), respectively. In addition, the corresponding IDI were 0.125 (p=0.0019) and 0.078 (p=0.0002) and the corresponding NRI were 0.500 (p=0.0010) and 0.351 (p=0.0020) in 5- and 10-years, respectively. In the validation set, the nomogram worked well, and the AUROCs for 5- and 10-years prediction were 0.75 (95% CI: 0.67-0.83) and 0.77 (95% CI: 0.71-0.84), respectively. Conclusions: Our developed nomogram performed well across cohorts, and may be applied to other HBV carrier populations. The risk score may be able to identify HBV-related cirrhosis with differing risk for HCC to assist in clinical decision-making process. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:48:34Z (GMT). No. of bitstreams: 1 ntu-105-R03849021-1.pdf: 1827650 bytes, checksum: 210de6153e0a9df03fdf3641d46c5aeb (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 #
致謝 i 中文摘要 ii ABSTRACT iv 目錄 vi 表目錄 viii 圖目錄 ix 第一章 研究背景 1 B型肝炎與肝細胞癌 1 肝硬化與肝細胞癌 1 治療與篩檢策略 3 肝細胞癌風險預測模型 4 第二章 研究目的 6 第三章 材料與方法 7 資料庫 7 分析流程與架構 8 資料處理與分析分法 8 第四章 結果 10 研究個案特性 10 肝硬化之肝細胞癌危險性 11 肝硬化世代之肝細胞癌危險因子分析 11 肝硬化者之肝細胞癌預測模型 12 預測模型之驗證與適合度檢定 13 第五章 討論 14 肝硬化的危險性 14 癌症篩檢與風險分層之應用 15 肝硬化者危險分數與篩檢治療策略 16 預測模式變項選取與模式的外推性 17 結論 18 參考文獻 19 | |
dc.language.iso | zh-TW | |
dc.title | B型肝炎病毒慢性感染之肝硬化引發肝細胞癌之決定因素與風險預測模型 | zh_TW |
dc.title | Hepatocellular Carcinoma in Hepatitis B-Related Liver Cirrhosis: Determinants and Predictive model | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李文宗,林志陵,黃奕文 | |
dc.subject.keyword | 肝硬化,B型肝炎,肝細胞癌,預測模式, | zh_TW |
dc.subject.keyword | Cirrhosis,Hepatitis B,Hepatocellular carcinoma,Prediction model, | en |
dc.relation.page | 35 | |
dc.identifier.doi | 10.6342/NTU201601490 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-08-02 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。